Patents by Inventor Neil Andrew Williams

Neil Andrew Williams has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Agent for Treating Allergic or Hypersensitivity Condition
    Publication number: 20150165010
    Abstract: The use of an agent in the manufacture of a medicament to affect an allergic condition and/or a hypersensitivity condition is described. The agent is capable of modulating a ganglioside associated activity. The agent is not coupled to an antigen. The modulation of the ganglioside associated activity affects an allergic condition and/or a hypersensitivity condition.
    Type: Application
    Filed: February 23, 2015
    Publication date: June 18, 2015
    Inventors: Neil Andrew Williams, Timothy Raymond Hirst, John Bienenstock
  • Agent for treating allergic or hypersensitivity condition
    Patent number: 8992940
    Abstract: The use of an agent in the manufacture of a medicament to affect an allergic condition and/or a hypersensitivity condition is described. The agent is capable of modulating a ganglioside associated activity. The agent is not coupled to an antigen. The modulation of the ganglioside associated activity affects an allergic condition and/or a hypersensitivity condition.
    Type: Grant
    Filed: January 18, 2013
    Date of Patent: March 31, 2015
    Assignee: Trident Pharmaceuticals, Inc.
    Inventors: Neil Andrew Williams, Timothy Raymond Hirst, John Bienenstock
  • Therapeutic Agents
    Publication number: 20140322274
    Abstract: A method for treating an rheumatoid arthritis in a mammalian subject in need of same wherein the method comprises: administering to the mammalian subject an agent capable of modulating a ganglioside GM-1 associated activity in an amount effective to treat the disease.
    Type: Application
    Filed: December 10, 2013
    Publication date: October 30, 2014
    Inventors: Neil Andrew Williams, Timothy Raymond Hirst, Toufic Osman Nashar
  • Agent for treating allergic or hypersensitivity condition
    Patent number: 8357372
    Abstract: The use of an agent in the manufacture of a medicament to affect an allergic condition and/or a hypersensitivity condition is described. The agent is capable of modulating a ganglioside associated activity. The agent is not coupled to an antigen. The modulation of the ganglioside activity affects an allergic condition and/or a hypersensitivity condition.
    Type: Grant
    Filed: March 27, 2007
    Date of Patent: January 22, 2013
    Assignee: Trident Pharmaceuticals, Inc.
    Inventors: Neil Andrew Williams, Timothy Raymond Hirst, John Bienenstock
  • VACCINE
    Publication number: 20110223194
    Abstract: A method for stimulating the immune response to a vaccine applied to a mammalian subject includes the step of administering to the subject an effective amount of EtxB or a molecule having substantially equivalent activity, free from whole toxin and not linked to an antigen.
    Type: Application
    Filed: March 1, 2011
    Publication date: September 15, 2011
    Inventors: Timothy Raymond HIRST, Neil Andrew Williams, Andrew Morgan, Andrew Douglas Wilson, Lucy Amber Bird
  • Vaccine
    Patent number: 7914791
    Abstract: A method for stimulating the immune response to a vaccine applied to a mammalian subject includes the step of administering to the subject an effective amount of EtxB or a molecule having substantially equivalent activity, free from whole toxin and not linked to an antigen.
    Type: Grant
    Filed: May 10, 1999
    Date of Patent: March 29, 2011
    Assignee: Trident Pharmaceuticals, Inc.
    Inventors: Timothy Raymond Hirst, Neil Andrew Williams, Andrew Morgan, Andrew Douglas Wilson, Lucy Amber Bird
  • THERAPEUTIC AGENTS
    Publication number: 20100136023
    Abstract: A method for treating an rheumatoid arthritis in a mammalian subject in need of same wherein the method comprises: administering to the mammalian subject an agent capable of modulating a ganglioside GM-1 associated activity in an amount effective to treat the disease.
    Type: Application
    Filed: September 14, 2009
    Publication date: June 3, 2010
    Applicant: TRIDENT PHARMACEUTICALS, INC.
    Inventors: NEIL ANDREW WILLIAMS, TIMOTHY RAYMOND HIRST, TOUFIC OSMAN NASHAR
  • PHARMACEUTICAL COMPOUNDS
    Publication number: 20100087476
    Abstract: This application describes methods of treatment and/or prophylaxis of asthma that involve administration of dihydrotetrabenazine, and isomers and/or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: September 8, 2009
    Publication date: April 8, 2010
    Applicant: Biovail Laboratories International (Barbados) S.R.L.
    Inventors: Andrew John Duffield, Neil Andrew Williams
  • Methods for the prevention against or treatment of diabetes with ETXB and/or insulin
    Patent number: 7588763
    Abstract: This application relates to methods for modulating an immune response in a mammalian subject in need of prevention against or treatment of diabetes comprising the administration of EtxB and/or insulin.
    Type: Grant
    Filed: September 30, 2005
    Date of Patent: September 15, 2009
    Assignee: Trident Pharmaceuticals, Inc.
    Inventors: Neil Andrew Williams, Timothy Raymond Hirst, Toufic Osman Nashar
  • Agent For Treating Allergic or Hypersensitivity Condition
    Publication number: 20080206284
    Abstract: The use of an agent in the manufacture of a medicament to affect an allergic condition and/or a hypersensitivity condition is described. The agent is capable of modulating a ganglioside associated activity. The agent is not coupled to an antigen. The modulation of the ganglioside activity affects an allergic condition and/or a hypersensitivity condition.
    Type: Application
    Filed: March 27, 2007
    Publication date: August 28, 2008
    Inventors: Neil Andrew Williams, Timothy Raymond Hirst, John Bienenstock
  • Agent for treating allergic or hypersensitivity condition
    Patent number: 7208155
    Abstract: The use of an agent in the manufacture of a medicament to affect an allergic condition and/or a hypersensitivity condition is described. The agent is capable of modulating a ganglioside associated activity. The agent is not coupled to an antigen. The modulation of the ganglioside associated activity affects an allergic condition and/or a hypersensitivity condition.
    Type: Grant
    Filed: January 8, 1999
    Date of Patent: April 24, 2007
    Assignee: Trident Pharmaceuticals, Inc.
    Inventors: Neil Andrew Williams, Timothy Raymond Hirst, John Bienenstock
  • Therapeutic agents
    Publication number: 20010036917
    Abstract: A method for treating diabetes in a mammalian subject in need of same wherein the method comprises: administering to the mammalian subject an agent capable of modulating a ganglioside GM-1 (GM-1) associated activity in an amount effect to treat the disease; wherein the agent, when in vivo, has an effect on GM-1 mediated intracellular signalling events; and wherein if the agent is for co-administration with an antigen, then the agent and the antigen are not so linked to form a single active agent.
    Type: Application
    Filed: May 30, 2001
    Publication date: November 1, 2001
    Inventors: Neil Andrew Williams, Timothy Raymond Hirst, Toufic Osman Nashar
  • Therapeutic agents and autoimmune diseases
    Patent number: 6287563
    Abstract: There is disclosed the use, as an agent in the treatment or the prevention of an autoimmune disease, of: (i) an agent having GM-1 binding activity, other than Ctx or Etx, or the B subunits of Ctx and Etx; or (ii) an agent having an effect on GM-1 mediated intracellular signalling events, but no GM-1 binding activity. These agents may also be used in the treatment of human T cell leukaemia, in the prevention of transplant rejection or GVHD or in a vaccination method for vaccinating a mammalian subject.
    Type: Grant
    Filed: December 29, 1997
    Date of Patent: September 11, 2001
    Inventors: Neil Andrew Williams, Timothy Raymond Hirst, Toufic Osman Nashar